Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study

Journal:

European Urology

Published:

2025-10-08

DOI:

10.1016/j.eururo.2025.09.4152

Affiliations:

19

Authors:

20

Go to article

Institutions	Authors	Share
Johnson & Johnson, United States of America (USA)	5.000000	0.25
USC Norris Comprehensive Cancer Center, United States of America (USA)	1.000000	0.05
University of Kansas Health System, United States of America (USA)	1.000000	0.05
The University of Sheffield, United Kingdom (UK)	1.000000	0.05
Medical University of Gdańsk (MUG), Poland	1.000000	0.05
The University of Texas Southwestern Medical Center (UT Southwestern Medical Center), United States of America (USA)	1.000000	0.05
Gunma Prefectural Cancer Center, Japan	1.000000	0.05
Emory University, United States of America (USA)	1.000000	0.05
Peter MacCallum Cancer Centre (Peter Mac), Australia	1.000000	0.05
Johnson & Johnson, Belgium, Belgium	1.000000	0.05
Center for Clinical Medical Education and Research (CEMIC), Argentina	1.000000	0.05
Sant'Andrea Hospital, Italy	1.000000	0.05
IRCCS National Cancer Institute (INT) Milan, Italy	1.000000	0.05
Institut Paoli-Calmettes (IPC), France	1.000000	0.05
University of Pittsburgh Medical Center (UPMC), United States of America (USA)	1.000000	0.05
Lister Hospital, East and North Herts NHS Trust, United Kingdom (UK)	0.500000	0.03
University of Hertfordshire (UH), United Kingdom (UK)	0.500000	0.03

Interested in Oncology and Carcinogenesis?